The latter is comparing frontline amivantamab plus lazertinib versus osimertinib alone in treatment-naïve patients with advanced NSCLC with common EGFR mutations (NCT04487080) [115]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.